ReviewCancers2026

Efficacy and Toxicity of CDK4/6 Inhibitors in Early and Metastatic HR+/HER2- Breast Cancer: An Updated Meta-Analysis of Phase III Trials.

Ravneet K Dhanoa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.